CSTL Castle Biosciences

Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned a second consecutive Arizona Top Workplace award from AZ Central, the digital home of The Arizona Republic newspaper.

“We are thrilled to have once again been recognized as a Top Workplace in Arizona; this award is especially meaningful as it is based on feedback from our employees and is a testament to our unique workplace culture,” said Derek Maetzold, president and chief executive officer at Castle Biosciences. “We are truly grateful for our exceptional Castle team members who believe in our vision of keeping people first and show up each day, passionate about improving patient care.”

Top Workplace designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures 15 culture drivers that are indicative of successful organizations, such as alignment, execution and connection. Castle’s survey participation rate of 89% and employee engagement score of 81% were both well above the benchmark averages of 59% and 53%, respectively, for other similar healthcare companies participating in the Top Workplaces program.

Earlier this year, Castle also earned five Top Workplaces Culture Excellence Awards for continued excellence in the following areas of its workplace culture:

  • Innovation, for creating a culture where new ideas are encouraged, which helps employees to reach their full potential and benefits performance.
  • Work-Life Flexibility, for building a culture that enables employees to meet the demands of their personal lives while maintaining high performance.
  • Compensation & Benefits, for providing packages employees believe are fair for the work being done and compared to others in the industry.
  • Leadership, for organizational leaders who inspire confidence in employees and the company direction, listening to what matters most to employees and using that insight in decision making.
  • Purpose & Values, for successfully communicating the company mission and integrating those aspirations into the culture.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit and connect with us on , , and .

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

About Energage

Making the world a better place to work together.™

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 16 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit or .

EN
17/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for ...

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of ...

 PRESS RELEASE

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle Biosciences Celebrates Skin Cancer Awareness Month The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May Castle highlights cancer journey of melanoma survivor and advocate, Leah Adams   FRIENDSWOOD, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is recognizing Skin Cancer Awareness Month this May by supporting a series of initiatives designed to raise awaren...

 PRESS RELEASE

Castle Biosciences Reports First Quarter 2025 Results

Castle Biosciences Reports First Quarter 2025 Results Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial ...

 PRESS RELEASE

Castle Biosciences to Acquire Previse

Castle Biosciences to Acquire Previse Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflu...

 PRESS RELEASE

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Abi...

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC” FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its TissueCy...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch